Aspirin Could Decry Cancer Risk

Aspirin, a popular drug to treat headaches increasingly popular as a study stating that Aspirin is a drug that can control heart attack.

Aspirin is now getting to the top of its popularity after one of the drugs included in the prevention and treatment of cancer. 3 British researchers led by Dr. Peter M. Rothwell, a professor of neurology at the University of Oxford and John Radcliffe Hospital in Oxford, said.

A report published in The Lancet and The Lancet Ontology Rothwell stated that the team has analyzed the data 51 clinical trial, comparing aspirin with no aspirin in preventing heart attacks.

In another study, the team looked at the effects of asprin Rothwell in slowing the spread of cancer or metastasis. Their data from five clinical trials were also observed daily low-dose aspirin (75 milligrams or more) and the prevention of heart attack and stroke.

The researchers focused on patients who developed cancer. For more than 7 years of follow-up, low-dose aspirin reduces the risk of metastasis by 35%, compared with cancer patients who received placebo.

In addition, aspirin reduces the risk of metastasis in solid tumors, such as colon cancer, lung and prostate, by 46% and by 18% for patients with bladder cancer and kidney.

Aspirin also reduces the risk of cancer diagnosis had a 31% spread. For those who continue to use aspirin after the diagnosis of cancer, the risk of metastasis was reduced by 69%, according to the researchers.

Aspirin also reduces the risk of dying from cancer to about half. Reducing this risk remained after accounting for age and sex.

In the third study, Rothwell’s team looked at the effect of aspirin on metastasis by analyzing observational studies, not clinical trials.

These studies revealed 38% reduction in colon cancer, according to the risk reduction seen in clinical trials, they said. There were similar findings for cancer of the esophagus, stomach, bladder and breast, they added.

Although the research is to get attention, not everyone agrees with the overall conclusion. Among them was Nancy R. Cook, a biostatistician at Brigham and Women’s Hospital and Harvard Medical School in Boston.

He points out that these studies dealt with only by experiments in which aspirin is given daily, but two large studies in which aspirin is given every other day did not have a relationship with cancer prevention.

“Aspirin seems to work for people who have cardiovascular disease. Maybe in the long run turn out to be protective for cancer, but we need to make it and get more information,” said Cook.

Aspirin and unfriendly, says Cook, showed the risk of bleeding and other digestive problems. People should not start taking aspirin in the hope of preventing cancer, says Cook. “Most of these studies showed that the effect was not collected until after 10 years,” he noted.

Eric Jacobs, strategic director of pharmacoepidemiology for the American Cancer Society said: “This study provides important new evidence that aspirin every day for the long term, even at low doses, can lower the risk of developing cancer.”

“Because of these new results to take a broader community of scientists to evaluate these data in the context of existing knowledge and to consider whether clinical guidelines need to be changed,” said Jacobs.